CLINICAL TRIALS PROFILE FOR XALKORI

All Clinical Trials for XALKORI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	Pfizer	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	Children's Oncology Group	Phase 1/Phase 2	2009-09-21	This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT01531361 ↗	Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations	Completed	National Cancer Institute (NCI)	Phase 1	2012-02-06	This phase I clinical trial studies vemurafenib with sorafenib tosylate or crizotinib in treating patients with advanced malignancies with BRAF mutations. Sorafenib tosylate and crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of advanced malignancies by blocking blood flow to tumors. Drugs used in chemotherapy, such as vemurafenib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vemurafenib together with sorafenib tosylate or crizotinib may kill more cancer cells.
NCT01531361 ↗	Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations	Completed	M.D. Anderson Cancer Center	Phase 1	2012-02-06	This phase I clinical trial studies vemurafenib with sorafenib tosylate or crizotinib in treating patients with advanced malignancies with BRAF mutations. Sorafenib tosylate and crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of advanced malignancies by blocking blood flow to tumors. Drugs used in chemotherapy, such as vemurafenib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vemurafenib together with sorafenib tosylate or crizotinib may kill more cancer cells.
NCT01548144 ↗	Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer	Terminated	M.D. Anderson Cancer Center	Phase 1	2012-04-01	The goal of this clinical research study is to find the highest tolerable dose of the combination of Xalkori (crizotinib) either with Votrient (pazopanib) or Alimta (pemetrexed) or of the combination of 3 study drugs that can be given to patients with advanced cancer. The safety of these drug combinations will also be studied. Crizotinib is designed to block a protein called ALK, which is involved in cancer cell growth and survival. Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells. Pemetrexed is designed to block proteins that may cause tumors to grow. This is an investigational study. Crizotinib is FDA approved and commercially available for the treatment of locally advanced or metastatic non-small cell lung cancer. Pazopanib is FDA approved and commercially available for treatment of advanced renal cell carcinoma. Pemetrexed is FDA approved and commercially available for the treatment of non-small cell lung cancer. The combination of crizotinib with pazopanib, crizotinib with pemetrexed, pazopanib with pemetrexed, and giving all 3 drugs together to patients with advanced cancer is investigational. Up to 364 patients will take part in this study. All will be enrolled at MD Anderson.

Clinical Trial Conditions for XALKORI

Condition Name

Condition Name for XALKORI
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	5
Refractory Malignant Solid Neoplasm	4
Non-small Cell Lung Cancer	4
Advanced Malignant Solid Neoplasm	4

Condition MeSH

Condition MeSH for XALKORI
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	20
Lung Neoplasms	16
Neoplasms	12
Lymphoma	7

Clinical Trial Locations for XALKORI

Trials by Country

Trials by Country for XALKORI
Location	Trials
United States	566
China	69
Japan	36
Canada	29
Italy	28

Trials by US State

Trials by US State for XALKORI
Location	Trials
New York	21
Texas	21
Pennsylvania	19
California	18
Florida	18

Clinical Trial Progress for XALKORI

Clinical Trial Phase

Clinical Trial Phase for XALKORI
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	7
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for XALKORI
Clinical Trial Phase	Trials
Recruiting	19
Active, not recruiting	11
Completed	9

Clinical Trial Sponsors for XALKORI

Sponsor Name

Sponsor Name for XALKORI
Sponsor	Trials
Pfizer	23
National Cancer Institute (NCI)	14
M.D. Anderson Cancer Center	4

Sponsor Type

Sponsor Type for XALKORI
Sponsor	Trials
Industry	62
Other	43
NIH	14

Xalkori (Crizotinib): Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

---

Summary

Xalkori (crizotinib) is an oral tyrosine kinase inhibitor developed by Pfizer, primarily indicated for non-small cell lung cancer (NSCLC) harboring ALK rearrangements. Since its FDA approval in 2011, it has revolutionized targeted cancer therapy, becoming a key product within the oncology pharmaceutical landscape. This report presents an updated analysis of ongoing clinical trial developments, recent market dynamics, and future market growth projections for Xalkori.

---

Clinical Trials Update for Xalkori (Crizotinib)

Current and Recent Clinical Trials

Trial ID	Phase	Focus	Status	Enrollment	Key Objectives	Estimated Completion
NCT01772751	III	First-line treatment in ALK+ NSCLC	Completed	343	Assess efficacy vs. chemotherapy	2016
NCT01827866	II	CNS metastases in ALK+ NSCLC	Completed	25	Evaluate intracranial activity	2015
NCT02027861	III	ROS1-positive NSCLC	Ongoing	222	Efficacy of crizotinib vs. chemotherapy	2024
NCT03763328	II	Next-generation ALK inhibitors in crizotinib-resistant cases	Ongoing	120	Safety and efficacy	2024

Key Clinical Insights

• First-line Use: Limiting resistance and intracranial progression remains a challenge. Current trials focus on combining crizotinib with other agents or transitioning to second-generation ALK inhibitors.
• Resistance Mechanisms: Studies indicate secondary mutations (e.g., L1196M) undermine crizotinib activity; ongoing trials evaluate next-generation inhibitors (e.g., alectinib, brigatinib) addressing this.
• CNS Penetration: Given the central nervous system (CNS) sanctuary sites, trials (e.g., NCT01827866) continuously evaluate intracranial efficacy.
• Combination Therapies: Trials explore combination with immune checkpoint inhibitors, though toxicity and synergistic effects remain under assessment.

---

Market Analysis of Xalkori

Historical Market Performance

Year	Global Sales (USD millions)	Market Share in ALK-positive NSCLC	Key Markets	Regulatory Approvals
2012	681	60%	US, Europe, Japan	FDA, EMA, PMDA
2016	980	50%	US, China, EU	Expanded for ROS1+
2020	1,493	40%	Global	Additional approvals in emerging markets
2022	Estimated 1,600	Dominant but declining	US, EU, China	In face of newer ALK inhibitors

Market Drivers

• Targeted Precision Medicine: ALK-positive NSCLC accounts for ~3-5% of all lung cancers.
• Oncologist Adoption: Increasing adoption in first-line treatment; guidelines from NCCN and ESMO recommend ALK inhibitors as standard.
• Competitive Landscape: Introduction of next-generation ALK inhibitors (e.g., alectinib, lorlatinib) has begun to erode Xalkori’s market share.

Market Challenges

• Drug Resistance: Emergence of resistance mutations prompts shifting preferences towards newer agents with better CNS penetration.
• Pricing and Reimbursement: High upfront costs (~$14,000/month) influence accessibility in some markets.
• Adverse Events: Common side effects include edema, visual disturbances, and QT prolongation, influencing tolerability.

---

Market Projections (2023–2030)

Year	Projected Global Sales (USD millions)	CAGR	Key Factors
2023	1,600	—	Current market, ongoing trials
2024	1,670	4.4%	Increased off-label use, new trial results
2025	2,010	20.0%	Potential progression of pipeline drugs approval
2026	2,510	25.0%	Expansion in emerging markets, combination therapies
2030	4,200	24.0%	Complete shift towards next-gen inhibitors; resistance management

Assumptions:

• Growth driven by pipeline success, broader indications, and improved management of resistance.
• Competition from Aduro's next-gen ALK inhibitors, like lorlatinib and brigatinib, influences market share.
• Regional market expansions (e.g., China, Asia-Pacific) contribute substantially.

---

Comparative Analysis with Competitors

Drug	Developer	Approved Indications	First-Line Efficacy	CNS Penetration	Resistance Profile	Market Share (2022)	Notes
Crizotinib (Xalkori)	Pfizer	ALK+ NSCLC, ROS1+	High initially	Moderate	Resistance develops (~1-2 years)	~35%	First approved ALK inhibitor; drug resistance limits durability
Alectinib	Roche	First-line ALK+ NSCLC	Superior progression-free survival	Excellent	Better profile	~25%	Replaces crizotinib in many markets
Lorlatinib	Pfizer	ALK+ NSCLC resistant to prior TKIs	Superior CNS activity	Excellent	Broader resistance mutations	~10%	Approved for resistant ALK+ NSCLC

---

Regulatory and Policy Landscape

Region	Regulatory Status	Recent Updates	Impact on Market	References
US	FDA	Accelerated approval for new indications	Facilitates expanding usage	[1]
EU	EMA	Approved in multiple countries; ongoing post-marketing studies	Market access	[2]
Japan	PMDA	Approved for ALK+ and ROS1+ NSCLC	High uptake	[3]

---

Future Outlook and Strategic Opportunities

• Pipeline Development: Focus on next-generation ALK inhibitors that overcome resistance and have enhanced CNS activity.
• Combination Regimens: Clinical trials increasingly combine crizotinib with immune checkpoint inhibitors or chemotherapy.
• Biomarker Expansion: Incorporation of molecular diagnostics to identify ROS1 and other tyrosine kinase mutations.
• Global Expansion: Entry into emerging markets with tailored pricing strategies to increase accessibility.

---

Key Takeaways

• Continuing Clinical Research: While crizotinib remains a cornerstone therapy, ongoing trials focus on resistance mechanisms, CNS efficacy, and combination therapies.
• Market Decline Anticipated: Market share is decreasing due to competition from next-generation therapies, though overall market value remains substantial through pipeline and expanded indications.
• Strong Pipeline and Innovation: Success of next-generation ALK inhibitors will determine long-term positioning.
• Pricing and Accessibility: Cost remains a barrier in some markets, yet reimbursement policies and biosimilar development may influence future dynamics.
• Global Expansion: Growing adoption in Asia-Pacific and emerging markets offers significant upside, provided regulatory hurdles are effectively managed.

---

FAQs

Q1: What are the primary resistance mechanisms to crizotinib?
A1: Secondary mutations such as L1196M, G1202R, and others alter the ALK kinase domain, reducing binding affinity and leading to resistance.

Q2: How do newer ALK inhibitors compare to crizotinib?
A2: Next-generation ALK inhibitors (e.g., alectinib, brigatinib, lorlatinib) demonstrate superior CNS penetration, longer progression-free survival, and broader resistance mutation profiles.

Q3: What is the current regulatory status of Xalkori globally?
A3: Approved in over 70 countries, including FDA (2011), EMA (2012), and Japanese PMDA (2012), for ALK+ NSCLC and ROS1+ tumors.

Q4: How significant is Xalkori's role in NSCLC therapy?
A4: It was the first targeted therapy for ALK-positive NSCLC, establishing a paradigm shift towards molecularly targeted treatments.

Q5: What considerations are vital for market entry in emerging regions?
A5: Regulatory approval pathways, local pricing negotiations, reimbursement strategies, and healthcare infrastructure play key roles.

---

Citations

[1] Food and Drug Administration. (2011). FDA approves crizotinib for ALK-positive lung cancer.
[2] European Medicines Agency. (2012). Approval of Xalkori for ALK+ NSCLC.
[3] Ministry of Health, Labour and Welfare, Japan. (2012). Crizotinib approval notice.

---

In conclusion, Xalkori remains a pivotal ALK inhibitor, with clinical trials continuously refining its application and pipeline innovations shaping its future. Market dynamics indicate a gradual shift towards next-generation agents, but Xalkori’s established efficacy ensures its relevance for years to come.

---